Janssen to Showcase New Insights and Commitment to Accelerating Hope and Healing for Serious Mental Illness at Psych Congress 2023

Key analyses examine long-term safety and efficacy of medicines for treatment-resistant depression and schizophrenia TITUSVILLE, N.J., Sept. 5, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson will showcase data from its neuropsychiatry portfolio at Psych…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.